News & Updates

November 18, 2019

CR Medicon Expands Pharmacovigilance Management Capability in China With Oracle Argus

Nanjing, China Nov. 12, 2019 Nanjing CR Medicon Pharmaceutical Technology CO., Ltd., a Gold level member of Oracle […]
April 13, 2021

Why Conduct Clinical Trials in China? A Patient Recruitment Perspective

China-based pharmaceutical companies have experienced noteworthy success in achieving patient recruitment milestones, even in the […]
April 2, 2021
Regulatory

Why Conduct Clinical Trials in China? A Regulatory Perspective

The ongoing pandemic has changed the landscape of clinical development in prominent ways. Conducting clinical […]
November 19, 2020

Predicine and CR Medicon form strategic partnership to accelerate global Clinical Trials and Registration Approval

On November 11, 2020, CR Medicon and  Predicine jointly announced that it has entered into […]
April 6, 2020

Webinar: China NMPA and US FDA Emergency Approval and Implications to Life Science Companies Relating to COVID-19

Time: Tue, 07 April 2020 11:00 AM – 12:30 PM (EST) As COVID-19 has become […]
December 26, 2019
ADR ADE

China Annual ADR & ADE Monitoring Report (2018)

NMPA released an annual report on ADR & ADE monitoring in China (the 2018 version). […]
December 25, 2019
US-China Clinical Trial

US-China Clinical Trial Regulatory Overview

In this publication, we give a side-by-side comparative overview of clinical trial regulatory commonalities and […]
December 21, 2019
chemical drug

Innovative Chemical Drug Development in China

Compared with generic drugs, the development of innovative chemical drugs is more difficult, expensive, and […]
December 21, 2019
CRO in China

CRO in China – Leading the World with Rapid Growth

In recent years, the CRO (Contract Research Organization) industry in China has entered a “golden […]
中文